48985 - Homepage slide

Driving MASH Drug Development & Navigating
the Evolving Metabolic & Obesity Landscape

The MASH field have hailed the very first approved MASH therapeutic with Madrigal’s drug gaining FDA approval this March opening the doors to a wave of therapeutics from Eli Lilly, Boehringer Ingelheim, AstraZeneca, Amgen, Akero Therapeutics and more that hold huge promise in phase 1, 2, and 3 clinical trials.  

From optimizing clinical trial design, overcoming regulatory challenges, combatting fibrosis, navigating GLP-1 usage, optimizing RWE integration and achieving accurate non-invasive biomarkers, this Summit is your onestop-shop. The MASH therapeutic landscape has already been shaken up in 2024, and the 8th MASH Drug Development Summit is the venue for the community to unite and discuss the evolving drug development opportunity for MASH and metabolic diseases.   

Featuring 35+ World-Class Speakers

Who's Attended in the Past?

ASTRAZENECA
Boehringer Ingelheim logo
PFIZER
bms_logo_rgb_pos_300
BAYER
Eli_Lilly_and_Company
Amgen-Logo
GILEAD
Takeda_Pharmaceutical_Company_logo.svg
Regeneron-social-logo-1200x630
Akero Therapeutics, Inc. Logo
89bio
INVENTIVA
N_SGMT

Testimonials

Our Partners

summit clinical research
Antaros_Medical_logotype_RGB
Perspectum_Logo
physio
Almac-logo-sq-300x300
KBI_Logo
gubra

Other Events In The Series